Flavoring agent dihydrocoumarin alleviates IgE-mediated mast cell activation and allergic inflammation.
Chu-Chu XieBo-Ping ZhangHui-Na WangWei-Yong LiZe-Lang CaiYong HeKunmei JiJia-Jie ChenPublished in: Food & function (2022)
Mast cells (MCs) are the main effector cells in the onset of high-affinity receptor for IgE (FcεRI)-mediated allergic diseases. The aim of this study was to test whether dihydrocoumarin (DHC), a food flavoring agent derived from Melilotus officinalis , can block IgE-induced MC activation effects and to examine the potential molecular mechanisms by which DHC affects MC activation. Rat basophilic leukemia cells (RBLs) and mouse bone marrow-derived mast cells (BMMCs) were sensitized with anti-dinitrophenol (DNP) immunoglobulin (Ig)E antibodies, stimulated with DNP-human serum albumin antigen, and treated with DHC. Western blot analyses were performed to detect the expression of signaling proteins. Murine IgE-mediated passive cutaneous anaphylaxis (PCA) and ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) models were used to examine DHC effects on allergic reactions in vivo . DHC inhibited MC degranulation, as evidenced by reduced β-hexosaminidase activity and histamine levels, and reduced morphological changes associated with MC activation, namely cellular elongation and F-actin reorganization. DHC inhibited the activation of MAPK, NF-κB, and AP-1 pathways in IgE-activated MCs. Additionally, DHC could attenuate IgE/Ag-induced allergic reactions (dye extravasation and ear thickening) in PCA as well as OVA challenge-induced reactions in ASA mice (body temperature, serum histamine and IL-4 secretion changes). In conclusion, DHC suppressed MC activation. DHC may represent a new MC-suppressing treatment strategy for the treatment of IgE-mediated allergic diseases.
Keyphrases
- high glucose
- diabetic rats
- oxidative stress
- induced apoptosis
- signaling pathway
- allergic rhinitis
- drug induced
- type diabetes
- bone marrow
- human serum albumin
- acute myeloid leukemia
- immune response
- atopic dermatitis
- dendritic cells
- inflammatory response
- risk assessment
- transcription factor
- skeletal muscle
- metabolic syndrome
- mouse model
- cell death
- newly diagnosed
- cell proliferation
- combination therapy
- climate change